openPR Logo
Press release

Malaria Vaccines Market – Global Industry Analysis 2024

01-17-2017 03:53 PM CET | Health & Medicine

Press release from: Malaria Vaccines Market

Malaria Vaccines Market – Global Industry Analysis 2024

Today nearly 40% of the global population is at risk of malaria. According to the World Health Organization (WHO), there were nearly 214 million malaria cases in 2015 and approximately 4,38,000 malarial deaths globally. More than 70% of these deaths occur in children under 5 years of age. The Sub-Saharan Africa carries the highest share of global malaria burden with nearly 89% of malaria cases and 91% of malarial deaths in 2015. Such high impact of this life threatening disease has brought companies, investors and non-profit organizations to contribute towards curbing this disease spread. Treatment therapies include Artemisinin-based combination therapies (ACTs), chloroquine and primaquine. Moreover, recurrence of this disease has led to drug resistance leading to death of the patient. Therefore, prevention is the major focus of government, researchers and drug companies. The WHO estimates that increase in the prevention control and measure has led to a 60% reduction in malaria mortality since 2000.

Get Free PDF Research Brochure for more Professional and Technical Insights: https://www.coherentmarketinsights.com/insight/request-sample/37

Mosquirix – the First Malaria Vaccine

The quest for malaria vaccine at the GlaxoSmithKline started in 1984. In collaboration with the non-profit PATH Malaria Vaccine Initiative and funding from Bill & Melinda Gates Foundation, GlaxoSmithKline developed the first malarial vaccine.

Mosquirix, also known as RTS,S, was in development for about 30 years. Nearly, about USD 565 million has been invested in developing this vaccine. Bill and Melinda Gates Foundation contributed more than USD 200 million in this project. Mosquirix received marketing approval from the European authorities in July 2015. However, the WHO has recommended the Mosquirix vaccine to be examined in a pilot study before introducing at large scale. The study is carried out in Africa, and has received a funding of USD 25 million from Gavi, a global Vaccine Alliance, bringing together public and private sectors towards a common goal.

Significant Market Potential in Africa, Latin America and Asia

Malaria vaccine seems to be the best solution to prevent the spread of malaria which poses challenges in terms of drug resistance, and risk of death. Moreover, people use bed nets, and indoor spraying to fight against the infection. Therefore, there is immense opportunity globally for malaria vaccines in population at risk - Infants (23 million births annually), pre-adolescent and early adolescent girls, pregnant women in sub-Saharan Africa, and population in Asia, Latin America, Africa, and Oceania. Furthermore, risk of transmission of the disease increases from the ‘traveller’ and military population travelling from the U.S., Europe, Japan, and Australia, a malaria free zone, to the highly prone developing countries. The global malaria vaccine market resembles the vaccines market dynamics where the major purchasers being the health and non-profit organizations.

More Malaria Vaccines under Development

Mosquirix is a great boon for population in regions which are highly prone to malaria infection. However, accessibility and low cost of this vaccine is essential to serve the large population in the highly prone developing regions. Sanaria Inc. is a biotechnology company which aims to develop and commercialize whole-parasite sporozoite vaccines against Plasmodium falciparum which causes 95% of the malaria cases. The company is in strong endeavor to make this vaccine available to mass markets as soon as possible. In addition, Mymetics Corporation, a Switzerland based vaccines developer uses its virosome platform technology to develop vaccines. There are two vaccine candidates in its pipeline of which one cleared the phase 1b clinical rail while the other is in its preclinical stage. Moreover, use of new technologies such as Nucleic acid vaccines, Proteosomes, and several new adjuvants could generate next-generation malaria vaccines.

Browse Research Report At : https://www.coherentmarketinsights.com/ongoing-insight/malaria-vaccines-market-37

Such global commitments will encourage investors around the world to contribute towards a global malaria eradication mission.

ABOUT US
COMPANY OVERVIEW
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. Our global team of over 100 research analysts and freelance consultants provide market intelligence from the very molecular country level and also provide a global perspective of the market. Our team is of the most vital cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive defusion training module.This allows for an objective and unbiased assessment of the market. We pride ourselves in my constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth path in the future.

CONTACT US
CORPORATE OFFICE :
Coherent Market Insights
303, Astral Court,Above Reliance Fresh,
Near Gaikwad Petrol Pump,
Aundh, Pune – 411045, India
Mail Id : sales@coherentmarketinsights.com
Visit Blog : http://globalresearchtrends.blogspot.in/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Malaria Vaccines Market – Global Industry Analysis 2024 here

News-ID: 414612 • Views: 313

More Releases from Malaria Vaccines Market

MALARIA VACCINES MARKET - GLOBAL INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTU …
Malaria Vaccines Market Overview More than 40% of the global population is at risk of malaria, according to the World Health Organization (WHO) malaria fact sheet and World Bank estimates. According to the World Health Organization (WHO), there were around 214 million malaria cases reported in 2015, leading to 438,000 deaths worldwide. Over 70% of these deaths occur in children under 5 years of age. Sub-Saharan Africa accounts for the highest
Malaria Vaccines Market, Company Analysis and Forecast to 2024
Malaria Vaccines Market Overview More than 40% of the global population is at risk of malaria, according to the World Health Organization (WHO) malaria fact sheet and World Bank estimates. According to the World Health Organization (WHO), there were around 214 million malaria cases reported in 2015, leading to 438,000 deaths worldwide. Over 70% of these deaths occur in children under 5 years of age. Sub-Saharan Africa accounts for the highest
Malaria Vaccines Market - Trends, Outlook, and Opportunity Analysis, 2016-2024
Malaria Vaccines Market Future Outlook Mosquirix is a great boon for population in the highly prone regions of malaria infection. However, accessibility and low cost of this vaccine is essential to serve the large population in the highly prone emerging economies. Sanaria Inc. is a biotechnology company which aims to develop and commercialize whole-parasite sporozoite vaccines against Plasmodium falciparum that causes 95% of malaria cases. Mymetics Corporation—a Switzerland-based vaccines developer—uses its
Malaria Vaccines Market - Global Industry Insights, Trends, Outlook, and Opportu …
Malaria Vaccines Market Overview More than 40% of the global population is at risk of malaria, according to the World Health Organization (WHO) malaria fact sheet and World Bank estimates. According to the World Health Organization (WHO), there were around 214 million malaria cases reported in 2015, leading to 438,000 deaths worldwide. Over 70% of these deaths occur in children under 5 years of age. Sub-Saharan Africa accounts for the highest

All 5 Releases